Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.42 |
| ▸ | CTH | P32929 | 2/20 | 0.42 |
| ▸ | CBS | P35520 | 1/20 | 0.42 |
| ▸ | THPO | P40225 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 3/20 | 0.40 |
| ▸ | BLM | P54132 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.36 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.36 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.35 |
| ▸ | GABRP | O00591 | 1/20 | 0.35 |
| ▸ | GABRD | O14764 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28386959 | 1.00 | TSHR (0.42) | TSHRCTHCBSTHPOTHRB | |
| SCHEMBL22806980 | 1.00 | TSHR (0.42) | TSHRCTHCBSTHPOTHRB | |
| SCHEMBL26111100 | 1.00 | TSHR (0.42) | TSHRCTHCBSTHPOTHRB | |
| SCHEMBL13599228 | 1.00 | TSHR (0.42) | TSHRCTHCBSTHPOTHRB | |
| SCHEMBL1170690 | 1.00 | TSHR (0.42) | TSHRCTHCBSTHPOTHRB | |
| SCHEMBL60430 | 1.00 | TSHR (0.42) | TSHRCTHCBSTHPOTHRB | |
| SCHEMBL164253 | 1.00 | TSHR (0.42) | TSHRCTHCBSTHPOTHRB | |
| Hydrochloric Acid SCHEMBL9788713 | 0.98 | THRB (0.44) | TSHRCTHCBSTHPOTHRB | |
| Hydrochloric Acid SCHEMBL17941286 | 0.98 | THRB (0.44) | TSHRCTHCBSTHPOTHRB | |
| SCHEMBL303946 | 0.95 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4043447-B1 | HALOGENATED TETRACYCLIC TRITERPENE DERIVATIVE, PREPARATION AND APPLICATION THEREOF | SHANGHAI QINGDONG BIOTECHNOLOGY CO LTD (CN) | 2026-01-21 | — | — | EP | disclosed |
| CN-116390742-A | Cyclic chemokine-9 derivatives | 拜耳公司 | 2023-07-04 | — | — | CN | disclosed |
| EP-4043447-A1 | HALOGENATED TETRACYCLIC TRITERPENE DERIVATIVE, PREPARATION AND APPLICATION THEREOF | Shanghai King-X Biotech Co., Ltd. (CN) | 2022-08-17 | — | — | EP | disclosed |
| US-20220177511-A1 | SERIES OF HALOGENATED TETRACYCLIC TRITERPENE DERIVATIVES AND THEIR PREPARATION AND APPLICATION | Shanghai Qingdong Biotechnology Co., Ltd. (CN) | 2022-06-09 | — | — | US | disclosed |
| US-20130280746-A1 | PEPTIDE-LIPID CONSTRUCTS AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | KODE BIOTECH LIMITED (NZ) | 2013-10-24 | — | — | US | disclosed |
| US-20130280746-A1 | PEPTIDE-LIPID CONSTRUCTS AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | KODE BIOTECH LIMITED (NZ) | 2013-10-24 | — | — | US | disclosed |
| US-8394594-B2 | Peptide-lipid constructs and their use in diagnostic and therapeutic applications | KODE BIOTECH LIMITED (NZ) | 2013-03-12 | — | — | US | disclosed |
| US-8394594-B2 | Peptide-lipid constructs and their use in diagnostic and therapeutic applications | KODE BIOTECH LIMITED (NZ) | 2013-03-12 | — | — | US | disclosed |
| US-20110171666-A1 | PEPTIDE-LIPID CONSTRUCTS AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | KODE BIOTECH LIMITED (NZ) | 2011-07-14 | — | — | US | disclosed |
| US-20110171666-A1 | PEPTIDE-LIPID CONSTRUCTS AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | KODE BIOTECH LIMITED (NZ) | 2011-07-14 | — | — | US | disclosed |
| US-20080176341-A1 | Method for Suppressing Intermolecular Nonspecific Interaction and for Intensifying Intermolecular Specific Interaction on Metal Surface | REVERSE PROTEMICS RESEARCH INSTITUTE CO., LTD. (JP) | 2008-07-24 | — | — | US | disclosed |
| US-20060177943-A1 | Method of inhibiting nonspecific interaction between molecules on solid phase support | REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD. (JP) | 2006-08-10 | — | — | US | disclosed |
| EP-1553412-A1 | METHOD OF INHIBITING NONSPECIFIC INTERACTION BETWEEN MOLECULES ON SOLID PHASE SUPPORT | Reverse Proteomics Research Institute Co., Ltd (JP) | 2005-07-13 | — | — | EP | disclosed |
| US-6197299-B1 | TARGET CELL IS CONTACTED WITH A TARGET CELL LYSIS EFFECTIVE AMOUNT OF A SOLUBLE MONOCLONAL ANTIBODY OR FRAGMENT CONJUGATE COVALENTLY LINKED BY PEPTIDE BOND LINKAGE TO A SUPERANTIGEN FOR THE LYSIS OF A TARGET CELL BY ASSISTANCE OF LYMPHOCYTES | PHARMACIA & UPJOHN AB (SE) | 2001-03-06 | — | — | US | disclosed |
| US-5858363-A | WHEREIN ANTIBODY IS SPECIFIC FOR CELL SURFACE STRUCTURE AND SUPERANTIGEN IS CAPABLE OF ACTIVATING CYTOTOXIC T-CELLS | PHARMACIA & UPJOHN AB (IT) | 1999-01-12 | — | — | US | disclosed |
| EP-0610179-B1 | TARGET SPECIFIC ANTIBODY-SUPERANTIGEN CONJUGATES AND THEIR PREPARATION | PHARMACIA AB (SE) | 1996-10-16 | — | — | EP | disclosed |
| EP-0610179-A1 | TARGET SPECIFIC ANTIBODY-SUPERANTIGEN CONJUGATES AND THEIR PREPARATION. | KABI PHARMACIA AB (SE) | 1994-08-17 | — | — | EP | disclosed |
| EP-0540612-A1 | HETEROBIFUNCTIONAL REAGENTS AND CONJUGATES WITH OXAALKYLENE UNITS FOR AMPHIPHILIC BRIDGE STRUCTURES | Pharmacia AB (SE) | 1993-05-12 | — | — | EP | disclosed |
| WO-1992001470-A1 | TARGET SPECIFIC ANTIBODY-SUPERANTIGEN CONJUGATES AND THEIR PREPARATION | KABI PHARMACIA AB (SE) | 1992-02-06 | — | — | WO | disclosed |
| WO-1992001474-A1 | HETEROBIFUNCTIONAL REAGENTS AND CONJUGATES WITH OXAALKYLENE UNITS FOR AMPHIPHILIC BRIDGE STRUCTURES | KABI PHARMACIA AB (SE) | 1992-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177511-A1 | SERIES OF HALOGENATED TETRACYCLIC TRITERPENE DERIVATIVES AND THEIR PREPARATION AND APPLICATION | AGTR1, VIP, AGT | TSHR 45/4885CTH 673/4885CBS 1755/4885 |
| US-20060177943-A1 | Method of inhibiting nonspecific interaction between molecules on solid phase support | CD2BP2, CD14, SPR | TSHR 1141/4885CTH 1425/4885CBS 3155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.